FDA accepts BioCryst application for berotralstat to prevent of HAE attacks

February 18, 2020

The FDA accepts for review BioCryst Pharmaceuticals’ (NASDAQ:BCRX) marketing application seeking approval of berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

The agency’s action date is December 3. No advisory committee meeting is planned.

Berotralstat is a selective inhibitor of plasma kallikrein.

Shares up 4% premarket on light volume.

https://seekingalpha.com/news/3542621-fda-accepts-biocryst-application-for-berotralstat-for-prevention-of-hae-attacks